{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:00:07Z","timestamp":1789988407790,"version":"4.0.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00660-8","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:08:52Z","timestamp":1789981732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets"],"prefix":"10.1007","volume":"34","author":[{"given":"Lili","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3735-615X","authenticated-orcid":false,"given":"Zhe","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"6","key":"660_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","volume":"32","author":"S Zhang","year":"2020","unstructured":"Zhang S, et al. Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020;32(6):720\u20138.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"660_CR2","first-page":"322","volume":"5","author":"J Wu","year":"2025","unstructured":"Wu J, et al. Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022. J Natl Cancer Cent. 2025;5(3):322\u20139.","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"660_CR3","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2214\/ajr.180.6.1801621","volume":"180","author":"H Kaur","year":"2003","unstructured":"Kaur H, et al. Diagnosis, staging, and surveillance of cervical carcinoma. AJR Am J Roentgenol. 2003;180(6):1621\u201331.","journal-title":"AJR Am J Roentgenol"},{"issue":"7623","key":"660_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/bmj.39337.615197.80","volume":"335","author":"P Petignat","year":"2007","unstructured":"Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007;335(7623):765\u20138.","journal-title":"BMJ"},{"key":"660_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2015.11.008","volume":"42","author":"HW Wieringa","year":"2016","unstructured":"Wieringa HW, et al. Breaking the DNA damage response to improve cervical cancer treatment. Cancer Treat Rev. 2016;42:30\u201340.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"660_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.critrevonc.2012.07.006","volume":"85","author":"I Diaz-Padilla","year":"2013","unstructured":"Diaz-Padilla I, et al. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol. 2013;85(3):303\u201314.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"660_CR7","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.esmoop.2022.100579","volume":"7","author":"C Gennigens","year":"2022","unstructured":"Gennigens C, et al. Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open. 2022;7(5):100579.","journal-title":"ESMO Open"},{"issue":"1","key":"660_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ygyno.2014.01.042","volume":"133","author":"D Lorusso","year":"2014","unstructured":"Lorusso D, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;133(1):117\u201323.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"660_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734\u201343.","journal-title":"N Engl J Med"},{"issue":"36","key":"660_CR10","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","volume":"41","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, et al. First-Line Pembrolizumab\u2009+\u2009Chemotherapy Versus Placebo\u2009+\u2009Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505\u201311.","journal-title":"J Clin Oncol"},{"issue":"10460","key":"660_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10460):1321\u201332.","journal-title":"Lancet"},{"issue":"1","key":"660_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024;391(1):44\u201355.","journal-title":"N Engl J Med"},{"issue":"2","key":"660_CR13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1128\/JVI.77.2.1551-1563.2003","volume":"77","author":"RA DeFilippis","year":"2003","unstructured":"DeFilippis RA, et al. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol. 2003;77(2):1551\u201363.","journal-title":"J Virol"},{"issue":"4","key":"660_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/modpathol.2016.221","volume":"30","author":"EK Enwere","year":"2017","unstructured":"Enwere EK, et al. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017;30(4):577\u201386.","journal-title":"Mod Pathol"},{"issue":"1","key":"660_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, et al. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1):109.","journal-title":"Cell Commun Signal"},{"issue":"7354","key":"660_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106\u20139.","journal-title":"Nature"},{"issue":"20","key":"660_CR17","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.4161\/cc.26309","volume":"12","author":"L Friboulet","year":"2013","unstructured":"Friboulet L, et al. ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle. 2013;12(20):3298\u2013306.","journal-title":"Cell Cycle"},{"key":"660_CR18","doi-asserted-by":"publisher","first-page":"3598417","DOI":"10.1155\/2020\/3598417","volume":"2020","author":"X Wen","year":"2020","unstructured":"Wen X, Liu S, Cui M. Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis. Biomed Res Int. 2020;2020:3598417.","journal-title":"Biomed Res Int"},{"issue":"5","key":"660_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/abbs\/gmy022","volume":"50","author":"M Su","year":"2018","unstructured":"Su M, et al. LncRNAs in DNA damage response and repair in cancer cells. Acta Biochim Biophys Sin (Shanghai). 2018;50(5):433\u20139.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"660_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/etm.2013.1374","volume":"7","author":"P Jiang","year":"2014","unstructured":"Jiang P, Yue Y. Human papillomavirus oncoproteins and apoptosis (Review). Exp Ther Med. 2014;7(1):3\u20137.","journal-title":"Exp Ther Med"},{"key":"660_CR21","doi-asserted-by":"crossref","unstructured":"Neophytou CM et al. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13(17):4363.","DOI":"10.3390\/cancers13174363"},{"issue":"2","key":"660_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/annonc\/mdg071","volume":"14","author":"H Sultana","year":"2003","unstructured":"Sultana H, et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol. 2003;14(2):214\u20139.","journal-title":"Ann Oncol"},{"key":"660_CR23","doi-asserted-by":"crossref","unstructured":"Pearson GW. Control of invasion by epithelial-to-mesenchymal transition programs during metastasis. J Clin Med. 2019;8(5):646.","DOI":"10.3390\/jcm8050646"},{"issue":"9","key":"660_CR24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/humu.24418","volume":"43","author":"M Dean","year":"2022","unstructured":"Dean M, Moitra K, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Hum Mutat. 2022;43(9):1162\u201382.","journal-title":"Hum Mutat"},{"issue":"1","key":"660_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, et al. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. 2022;22(1):166.","journal-title":"Cancer Cell Int"},{"key":"660_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12885-015-1272-3","volume":"15","author":"A Full\u00e1r","year":"2015","unstructured":"Full\u00e1r A, et al. Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression. BMC Cancer. 2015;15:256.","journal-title":"BMC Cancer"},{"key":"660_CR27","doi-asserted-by":"crossref","unstructured":"Jarosz-Biej M et al. Tumor microenvironment as a game changer in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212.","DOI":"10.3390\/ijms20133212"},{"key":"660_CR28","doi-asserted-by":"crossref","unstructured":"Guo F et al. The correlation between tumor-associated macrophage infiltration and progression in cervical carcinoma. Biosci Rep. 2021;41(5):BSR20203145.","DOI":"10.1042\/BSR20203145"},{"key":"660_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83\u201392.","journal-title":"Hypoxia (Auckl)"},{"issue":"1","key":"660_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"24","key":"660_CR31","first-page":"5580","volume":"21","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Liu X, Lu YX. MicroRNA-143 regulates the proliferation and apoptosis of cervical cancer cells by targeting HIF-1\u03b1. Eur Rev Med Pharmacol Sci. 2017;21(24):5580\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"660_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","volume":"24","author":"JS Mattick","year":"2023","unstructured":"Mattick JS, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430\u201347.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"660_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/EBC20200032","volume":"65","author":"H Yan","year":"2021","unstructured":"Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65(4):625\u201339.","journal-title":"Essays Biochem"},{"issue":"1","key":"660_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-020-01162-0","volume":"19","author":"K Liu","year":"2020","unstructured":"Liu K, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020;19(1):54.","journal-title":"Mol Cancer"},{"issue":"5","key":"660_CR35","doi-asserted-by":"publisher","first-page":"6263","DOI":"10.3390\/molecules19056263","volume":"19","author":"A Pedroza-Torres","year":"2014","unstructured":"Pedroza-Torres A, et al. MicroRNAs in cervical cancer: evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance. Molecules. 2014;19(5):6263\u201381.","journal-title":"Molecules"},{"key":"660_CR36","doi-asserted-by":"crossref","unstructured":"Scarth JA et al. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol. 2021;102(3):001540.","DOI":"10.1099\/jgv.0.001540"},{"issue":"7","key":"660_CR37","doi-asserted-by":"publisher","first-page":"e2557","DOI":"10.1371\/journal.pone.0002557","volume":"3","author":"X Wang","year":"2008","unstructured":"Wang X, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE. 2008;3(7):e2557.","journal-title":"PLoS ONE"},{"issue":"7645","key":"660_CR38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Albert Einstein College of Medicine, Analytical Biological Services. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378\u201384.","journal-title":"Nature"},{"key":"660_CR39","doi-asserted-by":"publisher","first-page":"e9234","DOI":"10.7717\/peerj.9234","volume":"8","author":"X Wen","year":"2020","unstructured":"Wen X, et al. Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer. PeerJ. 2020;8:e9234.","journal-title":"PeerJ"},{"key":"660_CR40","doi-asserted-by":"publisher","first-page":"1060909","DOI":"10.3389\/fcell.2022.1060909","volume":"10","author":"M Zhou","year":"2022","unstructured":"Zhou M, et al. The role of long noncoding RNAs in therapeutic resistance in cervical cancer. Front Cell Dev Biol. 2022;10:1060909.","journal-title":"Front Cell Dev Biol"},{"key":"660_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fonc.2020.00150","volume":"10","author":"ML Tornesello","year":"2020","unstructured":"Tornesello ML, et al. The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer. Front Oncol. 2020;10:150.","journal-title":"Front Oncol"},{"issue":"1","key":"660_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00795-022-00338-5","volume":"56","author":"M Someya","year":"2023","unstructured":"Someya M, et al. Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy. Med Mol Morphol. 2023;56(1):38\u201345.","journal-title":"Med Mol Morphol"},{"issue":"3","key":"660_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ygyno.2016.07.093","volume":"142","author":"A Pedroza-Torres","year":"2016","unstructured":"Pedroza-Torres A, et al. A microRNA expression signature for clinical response in locally advanced cervical cancer. Gynecol Oncol. 2016;142(3):557\u201365.","journal-title":"Gynecol Oncol"},{"key":"660_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ncrna.2024.10.004","volume":"11","author":"D Cust\u00f3dio","year":"2025","unstructured":"Cust\u00f3dio D, Duarte B, et al. Upregulation of long non-coding RNA ENSG00000267838 is related to the high risk of progression and non-response to chemoradiotherapy treatment for cervical cancer. Noncoding RNA Res. 2025;11:104\u201314.","journal-title":"Noncoding RNA Res"},{"issue":"5","key":"660_CR45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","volume":"17","author":"CW Whitney","year":"1999","unstructured":"Whitney CW, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339\u201348.","journal-title":"J Clin Oncol"},{"issue":"9284","key":"660_CR46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(01)05965-7","volume":"358","author":"JA Green","year":"2001","unstructured":"Green JA, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358(9284):781\u20136.","journal-title":"Lancet"},{"issue":"2","key":"660_CR47","first-page":"320","volume":"21","author":"P Tsikouras","year":"2016","unstructured":"Tsikouras P, et al. Cervical cancer: screening, diagnosis and staging. J buon. 2016;21(2):320\u20135.","journal-title":"J buon"},{"issue":"5","key":"660_CR48","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.3892\/ol.2016.5157","volume":"12","author":"DX Assad","year":"2016","unstructured":"Assad DX, et al. Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. Oncol Lett. 2016;12(5):4107\u201316.","journal-title":"Oncol Lett"},{"key":"660_CR49","doi-asserted-by":"crossref","unstructured":"Liu JJ et al. Inhibition of phosphatidylinositol 3-kinase (PI3K) signaling synergistically potentiates antitumor efficacy of paclitaxel and overcomes paclitaxel-mediated resistance in cervical cancer. Int J Mol Sci. 2019;20(14):3383.","DOI":"10.3390\/ijms20143383"},{"key":"660_CR50","doi-asserted-by":"publisher","first-page":"102088","DOI":"10.1016\/j.ctrv.2020.102088","volume":"90","author":"L Attademo","year":"2020","unstructured":"Attademo L, et al. Immunotherapy in cervix cancer. Cancer Treat Rev. 2020;90:102088.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"660_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/14737140.2022.2075348","volume":"22","author":"L Mutlu","year":"2022","unstructured":"Mutlu L, et al. Targeted treatment options for the management of metastatic\/persistent and recurrent cervical cancer. Expert Rev Anticancer Ther. 2022;22(6):633\u201345.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"660_CR52","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"660_CR53","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S106412","volume":"10","author":"H Zhu","year":"2016","unstructured":"Zhu H, et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885\u201395.","journal-title":"Drug Des Devel Ther"},{"issue":"15","key":"660_CR54","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"1","key":"660_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5(1):60.","journal-title":"Signal Transduct Target Ther"},{"key":"660_CR56","doi-asserted-by":"publisher","first-page":"629266","DOI":"10.3389\/fphar.2020.629266","volume":"11","author":"LY Li","year":"2020","unstructured":"Li LY, et al. DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol. 2020;11:629266.","journal-title":"Front Pharmacol"},{"issue":"1","key":"660_CR57","first-page":"107","volume":"34","author":"Y Torii","year":"2014","unstructured":"Torii Y, et al. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. Anticancer Res. 2014;34(1):107\u201315.","journal-title":"Anticancer Res"},{"issue":"51","key":"660_CR58","doi-asserted-by":"publisher","first-page":"e9402","DOI":"10.1097\/MD.0000000000009402","volume":"96","author":"H Ryu","year":"2017","unstructured":"Ryu H, et al. ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy. Med (Baltim). 2017;96(51):e9402.","journal-title":"Med (Baltim)"},{"key":"660_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CMAR.S152232","volume":"10","author":"YC Feng","year":"2018","unstructured":"Feng YC, et al. The relationship between the PD-1\/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag Res. 2018;10:105\u201313.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"660_CR60","doi-asserted-by":"publisher","first-page":"12876","DOI":"10.1038\/s41598-017-13232-3","volume":"7","author":"CB Prasad","year":"2017","unstructured":"Prasad CB, et al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep. 2017;7(1):12876.","journal-title":"Sci Rep"},{"issue":"1","key":"660_CR61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ygyno.2019.08.010","volume":"155","author":"A Bianchi","year":"2019","unstructured":"Bianchi A, et al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol. 2019;155(1):144\u201350.","journal-title":"Gynecol Oncol"},{"key":"660_CR62","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","volume":"10","author":"A Pal","year":"2019","unstructured":"Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2019;10:3116.","journal-title":"Front Microbiol"},{"issue":"1","key":"660_CR63","doi-asserted-by":"publisher","first-page":"14195","DOI":"10.1038\/s41598-020-71134-3","volume":"10","author":"M Shimada","year":"2020","unstructured":"Shimada M, et al. The human papillomavirus E6 protein targets apoptosis-inducing factor (AIF) for degradation. Sci Rep. 2020;10(1):14195.","journal-title":"Sci Rep"},{"issue":"12","key":"660_CR64","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00705-006-0821-0","volume":"151","author":"TO Garnett","year":"2006","unstructured":"Garnett TO, Duerksen-Hughes PJ. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol. 2006;151(12):2321\u201335.","journal-title":"Arch Virol"},{"issue":"2","key":"660_CR65","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1006\/bbrc.2000.2432","volume":"270","author":"Z Ding","year":"2000","unstructured":"Ding Z, et al. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells. Biochem Biophys Res Commun. 2000;270(2):415\u201320.","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"660_CR66","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1080\/15384101.2019.1688951","volume":"18","author":"Y Huang","year":"2019","unstructured":"Huang Y, et al. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle. 2019;18(24):3442\u201355.","journal-title":"Cell Cycle"},{"issue":"1","key":"660_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","volume":"19","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19(1):19.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"660_CR68","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.virol.2009.05.036","volume":"391","author":"K Hellner","year":"2009","unstructured":"Hellner K, et al. HPV16 E7 oncogene expression in normal human epithelial cells causes molecular changes indicative of an epithelial to mesenchymal transition. Virology. 2009;391(1):57\u201363.","journal-title":"Virology"},{"issue":"5","key":"660_CR69","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cellsig.2013.02.013","volume":"25","author":"K Liu","year":"2013","unstructured":"Liu K, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5):1264\u201371.","journal-title":"Cell Signal"},{"issue":"1","key":"660_CR70","doi-asserted-by":"publisher","first-page":"e87092","DOI":"10.1371\/journal.pone.0087092","volume":"9","author":"XF Liu","year":"2014","unstructured":"Liu XF, et al. Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells. PLoS ONE. 2014;9(1):e87092.","journal-title":"PLoS ONE"},{"issue":"7","key":"660_CR71","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1039\/c2mt20021j","volume":"4","author":"X Du","year":"2012","unstructured":"Du X, et al. Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1). Metallomics. 2012;4(7):679\u201385.","journal-title":"Metallomics"},{"issue":"7","key":"660_CR72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41419-018-0776-6","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang Q, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018;9(7):739.","journal-title":"Cell Death Dis"},{"key":"660_CR73","doi-asserted-by":"crossref","unstructured":"Sleeboom JJF et al. Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches. Dis Model Mech. 2018;11(3):dmm033100.","DOI":"10.1242\/dmm.033100"},{"key":"660_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1748-717X-4-29","volume":"4","author":"PC Lara","year":"2009","unstructured":"Lara PC, et al. Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol. 2009;4:29.","journal-title":"Radiat Oncol"},{"issue":"6","key":"660_CR75","first-page":"1350","volume":"7","author":"M Geretto","year":"2017","unstructured":"Geretto M, et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 2017;7(6):1350\u201371.","journal-title":"Am J Cancer Res"},{"key":"660_CR76","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.gore.2023.101138","volume":"45","author":"H Nishi","year":"2023","unstructured":"Nishi H, et al. Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15. Gynecol Oncol Rep. 2023;45:101138.","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"660_CR77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/15384101.2017.1395533","volume":"17","author":"C Feng","year":"2018","unstructured":"Feng C, et al. SOX9\/miR-130a\/CTR1 axis modulates DDP-resistance of cervical cancer cell. Cell Cycle. 2018;17(4):448\u201358.","journal-title":"Cell Cycle"},{"issue":"12","key":"660_CR78","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/kjm2.12593","volume":"38","author":"EY Wu","year":"2022","unstructured":"Wu EY, Huang LP, Bao JH. miR-96-5p regulates cervical cancer cell resistance to cisplatin by inhibiting lncRNA TRIM52-AS1 and promoting IGF2BP2. Kaohsiung J Med Sci. 2022;38(12):1178\u201389.","journal-title":"Kaohsiung J Med Sci"},{"issue":"10","key":"660_CR79","doi-asserted-by":"publisher","first-page":"e109299","DOI":"10.1371\/journal.pone.0109299","volume":"9","author":"Y Shen","year":"2014","unstructured":"Shen Y, et al. miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLoS ONE. 2014;9(10):e109299.","journal-title":"PLoS ONE"},{"issue":"1","key":"660_CR80","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/bjc.2013.308","volume":"109","author":"Y Shen","year":"2013","unstructured":"Shen Y, et al. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer. 2013;109(1):92\u20139.","journal-title":"Br J Cancer"},{"issue":"4","key":"660_CR81","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2015.03.004","volume":"459","author":"S Liu","year":"2015","unstructured":"Liu S, et al. miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 2015;459(4):679\u201385.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"660_CR82","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/CAD.0000000000000871","volume":"31","author":"Q Liu","year":"2020","unstructured":"Liu Q, Liu S, Wang D. Overexpression of microRNA-21 decreased the sensitivity of advanced cervical cancer to chemoradiotherapy through SMAD7. Anticancer Drugs. 2020;31(3):272\u201381.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"660_CR83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13046-017-0520-6","volume":"36","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, et al. iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5\/BTG3 signaling. J Exp Clin Cancer Res. 2017;36(1):48.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"660_CR84","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4314\/ahs.v23i2.28","volume":"23","author":"J Wu","year":"2023","unstructured":"Wu J, et al. Expression of miR-152 in cervical cancer and its influence on cisplatin resistance. Afr Health Sci. 2023;23(2):246\u201355.","journal-title":"Afr Health Sci"},{"issue":"9","key":"660_CR85","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1002\/jcb.28763","volume":"120","author":"F Shi","year":"2019","unstructured":"Shi F, et al. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2. J Cell Biochem. 2019;120(9):15018\u201326.","journal-title":"J Cell Biochem"},{"issue":"11","key":"660_CR86","first-page":"2690","volume":"6","author":"H Yang","year":"2016","unstructured":"Yang H, et al. MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am J Cancer Res. 2016;6(11):2690\u20139.","journal-title":"Am J Cancer Res"},{"key":"660_CR87","doi-asserted-by":"publisher","first-page":"794015","DOI":"10.3389\/fonc.2021.794015","volume":"11","author":"H Yang","year":"2021","unstructured":"Yang H, et al. HK2 Is a Crucial Downstream Regulator of miR-148a for the Maintenance of Sphere-Forming Property and Cisplatin Resistance in Cervical Cancer Cells. Front Oncol. 2021;11:794015.","journal-title":"Front Oncol"},{"key":"660_CR88","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.2147\/CMAR.S199659","volume":"11","author":"M Yu","year":"2019","unstructured":"Yu M, et al. MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin. Cancer Manag Res. 2019;11:6511\u20139.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"660_CR89","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3892\/ol.2021.12653","volume":"21","author":"Y Xu","year":"2021","unstructured":"Xu Y, et al. MicroRNA-125a-5p targets LIM kinase 1 to inhibit cisplatin resistance of cervical cancer cells. Oncol Lett. 2021;21(5):392.","journal-title":"Oncol Lett"},{"issue":"2","key":"660_CR90","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1038\/oncsis.2016.1","volume":"5","author":"Z Fan","year":"2016","unstructured":"Fan Z, et al. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis. 2016;5(2):e197.","journal-title":"Oncogenesis"},{"key":"660_CR91","doi-asserted-by":"publisher","first-page":"883445","DOI":"10.3389\/fphar.2022.883445","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, et al. Engineered Exosomes-Mediated Transfer of hsa-miR-320a Overcomes Chemoresistance in Cervical Cancer Cells via Targeting MCL1. Front Pharmacol. 2022;13:883445.","journal-title":"Front Pharmacol"},{"key":"660_CR92","doi-asserted-by":"publisher","first-page":"1544784","DOI":"10.1155\/2021\/1544784","volume":"2021","author":"X Zhu","year":"2021","unstructured":"Zhu X, et al. Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer. Dis Markers. 2021;2021:1544784.","journal-title":"Dis Markers"},{"issue":"3","key":"660_CR93","doi-asserted-by":"publisher","first-page":"247","DOI":"10.17219\/acem\/166673","volume":"33","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. miR-214-5p increases the radiosensitivity of cervical cancer by targeting ROCK1 expression. Adv Clin Exp Med. 2024;33(3):247\u201359.","journal-title":"Adv Clin Exp Med"},{"issue":"6","key":"660_CR94","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.febslet.2015.01.037","volume":"589","author":"C Ye","year":"2015","unstructured":"Ye C, et al. MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells. FEBS Lett. 2015;589(6):702\u20139.","journal-title":"FEBS Lett"},{"issue":"1","key":"660_CR95","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jcp.28957","volume":"235","author":"H Sun","year":"2020","unstructured":"Sun H, et al. miR-4429 sensitized cervical cancer cells to irradiation by targeting RAD51. J Cell Physiol. 2020;235(1):185\u201393.","journal-title":"J Cell Physiol"},{"key":"660_CR96","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.biopha.2018.06.033","volume":"105","author":"Y Wu","year":"2018","unstructured":"Wu Y, et al. Over-expression of miR-15a-3p enhances the radiosensitivity of cervical cancer by targeting tumor protein D52. Biomed Pharmacother. 2018;105:1325\u201334.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"660_CR97","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/2211-5463.12730","volume":"9","author":"FN Ding","year":"2019","unstructured":"Ding FN, et al. miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25A (CDC25A). FEBS Open Bio. 2019;9(11):1869\u201379.","journal-title":"FEBS Open Bio"},{"issue":"12","key":"660_CR98","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.32604\/or.2024.044547","volume":"32","author":"C Wang","year":"2024","unstructured":"Wang C, Zhang T, Zhang C. LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p\/EGFR axis. Oncol Res. 2024;32(12):1867\u201379.","journal-title":"Oncol Res"},{"issue":"7","key":"660_CR99","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/jog.15245","volume":"48","author":"MJ Zou","year":"2022","unstructured":"Zou MJ, Cheng XR, Liu RF. lncRNA DLG1-AS1 promotes cervical cancer cell gemcitabine resistance by regulating miR-16-5p\/HDGF. J Obstet Gynaecol Res. 2022;48(7):1836\u201347.","journal-title":"J Obstet Gynaecol Res"},{"key":"660_CR100","doi-asserted-by":"crossref","unstructured":"Mao BD et al. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci. 2019;44(2):44.","DOI":"10.1007\/s12038-019-9851-0"},{"key":"660_CR101","doi-asserted-by":"crossref","unstructured":"Shao X et al. Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a\/LDHA axis. Biosci Rep. 2021;41(7):BSR20200533.","DOI":"10.1042\/BSR20200533"},{"key":"660_CR102","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12935-020-01278-9","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1\/miR-186\/HMGB1 axis. Cancer Cell Int. 2020;20:190.","journal-title":"Cancer Cell Int"},{"key":"660_CR103","doi-asserted-by":"publisher","first-page":"777220","DOI":"10.3389\/fonc.2021.777220","volume":"11","author":"H Hou","year":"2021","unstructured":"Hou H, et al. LncRNA OTUD6B-AS1 Induces Cisplatin Resistance in Cervical Cancer Cells Through Up-Regulating Cyclin D2 via miR-206. Front Oncol. 2021;11:777220.","journal-title":"Front Oncol"},{"issue":"9","key":"660_CR104","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3724\/abbs.2025032","volume":"57","author":"B Wang","year":"2025","unstructured":"Wang B, et al. Long noncoding RNA UCA1 knockdown inhibits cisplatin-resistant cervical cancer tumorigenesis via the miR-195-5p\/IKBKB axis. Acta Biochim Biophys Sin (Shanghai). 2025;57(9):1492\u2013506.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"660_CR105","doi-asserted-by":"publisher","first-page":"784525","DOI":"10.3389\/fonc.2021.784525","volume":"11","author":"S He","year":"2021","unstructured":"He S, et al. The Role of the SOX9\/lncRNA ANXA2P2\/miR-361-3p\/SOX9 Regulatory Loop in Cervical Cancer Cell Growth and Resistance to Cisplatin. Front Oncol. 2021;11:784525.","journal-title":"Front Oncol"},{"key":"660_CR106","doi-asserted-by":"publisher","first-page":"6341011","DOI":"10.1155\/2023\/6341011","volume":"2023","author":"Y Hu","year":"2023","unstructured":"Hu Y, et al. Effect of Exosomal lncRNA MALAT1\/miR-370-3p\/STAT3 Positive Feedback Loop on PI3K\/Akt Pathway Mediating Cisplatin Resistance in Cervical Cancer Cells. J Oncol. 2023;2023:6341011.","journal-title":"J Oncol"},{"issue":"1","key":"660_CR107","doi-asserted-by":"publisher","first-page":"20541","DOI":"10.1038\/s41598-025-08727-3","volume":"15","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. MIR155HG promotes metastasis and cisplatin resistance of cervical cancer cells by regulating the miR-409-3p and ZEB1 axis. Sci Rep. 2025;15(1):20541.","journal-title":"Sci Rep"},{"key":"660_CR108","doi-asserted-by":"publisher","first-page":"110788","DOI":"10.1016\/j.cellsig.2023.110788","volume":"109","author":"S Shen","year":"2023","unstructured":"Shen S, et al. LINC00426, a novel m(6)A-regulated long non-coding RNA, induces EMT in cervical cancer by binding to ZEB1. Cell Signal. 2023;109:110788.","journal-title":"Cell Signal"},{"issue":"4","key":"660_CR109","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1002\/jcp.27198","volume":"234","author":"WY Zhang","year":"2019","unstructured":"Zhang WY, et al. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer. J Cell Physiol. 2019;234(4):4302\u201313.","journal-title":"J Cell Physiol"},{"issue":"1","key":"660_CR110","doi-asserted-by":"publisher","first-page":"e14424","DOI":"10.1111\/cbdd.14424","volume":"103","author":"P Tian","year":"2024","unstructured":"Tian P, Feng Y, Tao L. LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI. Chem Biol Drug Des. 2024;103(1):e14424.","journal-title":"Chem Biol Drug Des"},{"issue":"8","key":"660_CR111","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/1120009X.2024.2436803","volume":"37","author":"Z Xia","year":"2025","unstructured":"Xia Z, et al. LncRNA-FGD5-AS1 promotes 5-Fu resistance of cervical cancer cells through modulating the miR-130a-3p-YTHDF2 axis. J Chemother. 2025;37(8):710\u201322.","journal-title":"J Chemother"},{"issue":"11","key":"660_CR112","doi-asserted-by":"publisher","first-page":"152653","DOI":"10.1016\/j.prp.2019.152653","volume":"215","author":"M Li","year":"2019","unstructured":"Li M, et al. Enhancement of cisplatin-induced cytotoxicity against cervical cancer spheroid cells by targeting long non-coding RNAs. Pathol Res Pract. 2019;215(11):152653.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"660_CR113","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12935-021-02239-6","volume":"21","author":"H Lv","year":"2021","unstructured":"Lv H, et al. Analyzing the whole-transcriptome profiles of ncRNAs and predicting the competing endogenous RNA networks in cervical cancer cell lines with cisplatin resistance. Cancer Cell Int. 2021;21(1):532.","journal-title":"Cancer Cell Int"},{"key":"660_CR114","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12935-020-01448-9","volume":"20","author":"J Liu","year":"2020","unstructured":"Liu J, Liu X, Li R. LncRNA SNHG6 enhances the radioresistance and promotes the growth of cervical cancer cells by sponging miR-485-3p. Cancer Cell Int. 2020;20:424.","journal-title":"Cancer Cell Int"},{"key":"660_CR115","doi-asserted-by":"crossref","unstructured":"Lei HW et al. KCNQ1 opposite strand\/antisense transcript 1 promotes aggressive biological behaviors of cervical cancer cells via regulating microRNA-491-5p and pyruvate kinase M1\/2. J Biol Regul Homeost Agents, 2020. 34(5).","DOI":"10.23812\/20-19-A"},{"issue":"4","key":"660_CR116","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/15384101.2018.1442625","volume":"17","author":"X Wang","year":"2018","unstructured":"Wang X, et al. LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation. Cell Cycle. 2018;17(4):439\u201347.","journal-title":"Cell Cycle"},{"issue":"1","key":"660_CR117","doi-asserted-by":"publisher","first-page":"22604","DOI":"10.1038\/s41598-025-07213-0","volume":"15","author":"Y Ju","year":"2025","unstructured":"Ju Y, et al. LncRNA TMPO-AS1 facilitates cervical cancer cell tumorigenesis and ferroptosis resistance via interaction with LCN2. Sci Rep. 2025;15(1):22604.","journal-title":"Sci Rep"},{"issue":"1","key":"660_CR118","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000519844","volume":"211","author":"W Zhang","year":"2022","unstructured":"Zhang W, et al. LncRNA HOTAIR Promotes Chemoresistance by Facilitating Epithelial to Mesenchymal Transition through miR-29b\/PTEN\/PI3K Signaling in Cervical Cancer. Cells Tissues Organs. 2022;211(1):16\u201329.","journal-title":"Cells Tissues Organs"},{"issue":"2","key":"660_CR119","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-022-05547-5","volume":"14","author":"C Chi","year":"2023","unstructured":"Chi C, et al. PDHB-AS suppresses cervical cancer progression and cisplatin resistance via inhibition on Wnt\/\u03b2-catenin pathway. Cell Death Dis. 2023;14(2):90.","journal-title":"Cell Death Dis"},{"issue":"1","key":"660_CR120","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1186\/s12885-022-10188-0","volume":"22","author":"Y Du","year":"2022","unstructured":"Du Y, et al. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21\/PTEN axis. BMC Cancer. 2022;22(1):1145.","journal-title":"BMC Cancer"},{"issue":"6","key":"660_CR121","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1007\/s10528-024-11011-0","volume":"63","author":"H Wang","year":"2025","unstructured":"Wang H, et al. LncRNA PGM5-AS1 Impairs the Resistance of Cervical Cancer to Cisplatin by Regulating the Hippo and PI3K-AKT Pathways. Biochem Genet. 2025;63(6):5641\u201355.","journal-title":"Biochem Genet"},{"key":"660_CR122","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ijbiomac.2018.12.176","volume":"126","author":"J Gao","year":"2019","unstructured":"Gao J, et al. LncRNA GAS5 confers the radio sensitivity of cervical cancer cells via regulating miR-106b\/IER3 axis. Int J Biol Macromol. 2019;126:994\u20131001.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"660_CR123","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1080\/01443615.2022.2099257","volume":"42","author":"L Wu","year":"2022","unstructured":"Wu L, et al. CircRNA circ_0005273 contributes to the cisplatin resistance of cervical cancer cells by sponging miR-133b. J Obstet Gynaecol. 2022;42(7):3086\u201393.","journal-title":"J Obstet Gynaecol"},{"issue":"5","key":"660_CR124","first-page":"571","volume":"38","author":"Y Tang","year":"2023","unstructured":"Tang Y, Zhou L, Liu L. Circ_0085616 contributes to the radio-resistance and progression of cervical cancer by targeting miR-541-3p\/ARL2 signaling. Histol Histopathol. 2023;38(5):571\u201384.","journal-title":"Histol Histopathol"},{"issue":"11","key":"660_CR125","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/mc.23605","volume":"62","author":"T Ma","year":"2023","unstructured":"Ma T, et al. Circ_0001589\/miR-1248\/HMGB1 axis enhances EMT-mediated metastasis and cisplatin resistance in cervical cancer. Mol Carcinog. 2023;62(11):1645\u201358.","journal-title":"Mol Carcinog"},{"key":"660_CR126","first-page":"4807287","volume":"2022","author":"X Long","year":"2022","unstructured":"Long X, et al. circ_ZFR Is Linked to Paclitaxel Resistance in Cervical Cancer via miR-944 Sponging and IL-10 Upregulation. Anal Cell Pathol (Amst). 2022;2022:4807287.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"660_CR127","doi-asserted-by":"publisher","first-page":"5435333","DOI":"10.1155\/2022\/5435333","volume":"2022","author":"H Yi","year":"2022","unstructured":"Yi H, et al. Circular RNA circ_0004488 Increases Cervical Cancer Paclitaxel Resistance via the miR-136\/MEX3C Signaling Pathway. J Oncol. 2022;2022:5435333.","journal-title":"J Oncol"},{"issue":"6","key":"660_CR128","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1007\/s10528-022-10201-y","volume":"60","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, et al. Downregulation of Circ-CEP128 Enhances the Paclitaxel Sensitivity of Cervical Cancer Through Regulating miR-432-5p\/MCL1. Biochem Genet. 2022;60(6):2346\u201363.","journal-title":"Biochem Genet"},{"issue":"8","key":"660_CR129","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s43032-022-00855-9","volume":"29","author":"J Chen","year":"2022","unstructured":"Chen J, et al. Hsa_circ_0074269-mediated Upregulation of TUFT1 Through miR-485-5p Increases Cisplatin Resistance in Cervical Cancer. Reprod Sci. 2022;29(8):2236\u201350.","journal-title":"Reprod Sci"},{"issue":"6","key":"660_CR130","doi-asserted-by":"publisher","first-page":"187585922513411","DOI":"10.1177\/18758592251341157","volume":"42","author":"L Shang","year":"2025","unstructured":"Shang L, et al. Hsa_circ_0101308 adjusted by N6-methyladenosine (m(6)A) impacts chemo-resistance in cervical cancer via sponging miR-224. Cancer Biomark. 2025;42(6):18758592251341157.","journal-title":"Cancer Biomark"},{"issue":"1","key":"660_CR131","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15476286.2024.2399307","volume":"21","author":"R Gupta","year":"2024","unstructured":"Gupta R, et al. Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle? RNA Biol. 2024;21(1):17\u201328.","journal-title":"RNA Biol"},{"issue":"14","key":"660_CR132","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.7150\/thno.77350","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12(14):6422\u201336.","journal-title":"Theranostics"},{"issue":"1","key":"660_CR133","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13046-026-03640-7","volume":"45","author":"R Zhou","year":"2026","unstructured":"Zhou R, et al. Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity. J Exp Clin Cancer Res. 2026;45(1):33.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"660_CR134","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12885-017-3192-x","volume":"17","author":"W Wang","year":"2017","unstructured":"Wang W, et al. MiR-23b controls ALDH1A1 expression in cervical cancer stem cells. BMC Cancer. 2017;17(1):292.","journal-title":"BMC Cancer"},{"issue":"6","key":"660_CR135","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s43032-021-00820-y","volume":"29","author":"F Fang","year":"2022","unstructured":"Fang F, et al. Exosome-Mediated Transfer of miR-1323 from Cancer-Associated Fibroblasts Confers Radioresistance of C33A Cells by Targeting PABPN1 and Activating Wnt\/\u03b2-Catenin Signaling Pathway in Cervical Cancer. Reprod Sci. 2022;29(6):1809\u201321.","journal-title":"Reprod Sci"},{"key":"660_CR136","doi-asserted-by":"publisher","first-page":"109449","DOI":"10.1016\/j.abb.2022.109449","volume":"731","author":"J Ling","year":"2022","unstructured":"Ling J, et al. Human papillomavirus 16 E6\/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p\/PD-L1 axis. Arch Biochem Biophys. 2022;731:109449.","journal-title":"Arch Biochem Biophys"},{"key":"660_CR137","doi-asserted-by":"crossref","unstructured":"Konstantopoulos G et al. HPV16 E6 oncogene contributes to cancer immune evasion by regulating PD-L1 expression through a miR-143\/HIF-1a pathway. Viruses. 2024;16(1):113.","DOI":"10.3390\/v16010113"},{"issue":"1","key":"660_CR138","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ygyno.2019.04.651","volume":"154","author":"CT Lucido","year":"2019","unstructured":"Lucido CT, et al. Innervation of cervical carcinoma is mediated by cancer-derived exosomes. Gynecol Oncol. 2019;154(1):228\u201335.","journal-title":"Gynecol Oncol"},{"key":"660_CR139","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fonc.2020.00019","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T, et al. Schwann Cell-Derived CCL2 Promotes the Perineural Invasion of Cervical Cancer. Front Oncol. 2020;10:19.","journal-title":"Front Oncol"},{"issue":"8","key":"660_CR140","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41419-024-07030-9","volume":"15","author":"X Gao","year":"2024","unstructured":"Gao X, et al. Cervical cancer-produced neuromedin-B reprograms Schwann cells to initiate perineural invasion. Cell Death Dis. 2024;15(8):636.","journal-title":"Cell Death Dis"},{"issue":"1","key":"660_CR141","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-025-02241-8","volume":"10","author":"T Pu","year":"2025","unstructured":"Pu T, et al. Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications. Signal Transduct Target Ther. 2025;10(1):176.","journal-title":"Signal Transduct Target Ther"},{"key":"660_CR142","doi-asserted-by":"crossref","unstructured":"Patel M et al. LncRNAs at the frontline of neuroimmune crosstalk in oral cancer. Clin Exp Immunol. 2026;220(1):uxag007.","DOI":"10.1093\/cei\/uxag007"},{"issue":"11","key":"660_CR143","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jjco\/hyaa149","volume":"50","author":"M Someya","year":"2020","unstructured":"Someya M, et al. Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. Jpn J Clin Oncol. 2020;50(11):1290\u20137.","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"660_CR144","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630\u20137.","journal-title":"Br J Cancer"},{"issue":"10","key":"660_CR145","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386\u201396.","journal-title":"Lancet Oncol"},{"issue":"4","key":"660_CR146","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406\u201317.","journal-title":"Cancer Discov"},{"issue":"6","key":"660_CR147","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1634\/theoncologist.2018-0838","volume":"24","author":"I El Dika","year":"2019","unstructured":"El Dika I, et al. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. Oncologist. 2019;24(6):747\u2013e218.","journal-title":"Oncologist"},{"issue":"5","key":"660_CR148","first-page":"740","volume":"56","author":"S Jin","year":"2024","unstructured":"Jin S, et al. miR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer. Acta Biochim Biophys Sin (Shanghai). 2024;56(5):740\u201352.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"4","key":"660_CR149","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1248\/cpb.c20-00600","volume":"69","author":"J Xu","year":"2021","unstructured":"Xu J, et al. MiR-509-3p Induces Apoptosis and Affects the Chemosensitivity of Cervical Cancer Cells by Targeting the RAC1\/PAK1\/LIMK1\/Cofilin Pathway. Chem Pharm Bull (Tokyo). 2021;69(4):325\u201332.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"660_CR150","doi-asserted-by":"publisher","first-page":"783213","DOI":"10.3389\/fphar.2021.783213","volume":"12","author":"J Yang","year":"2021","unstructured":"Yang J, et al. MicroRNA-92a-3p Enhances Cisplatin Resistance by Regulating Kr\u00fcppel-Like Factor 4-Mediated Cell Apoptosis and Epithelial-to-Mesenchymal Transition in Cervical Cancer. Front Pharmacol. 2021;12:783213.","journal-title":"Front Pharmacol"},{"key":"660_CR151","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.12659\/MSM.910969","volume":"24","author":"F Yang","year":"2018","unstructured":"Yang F, et al. MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes. Med Sci Monit. 2018;24:6506\u201316.","journal-title":"Med Sci Monit"},{"key":"660_CR152","doi-asserted-by":"publisher","first-page":"470","DOI":"10.18632\/oncotarget.28608","volume":"15","author":"CL Duurland","year":"2024","unstructured":"Duurland CL, et al. INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death. Oncotarget. 2024;15:470\u201385.","journal-title":"Oncotarget"},{"issue":"31","key":"660_CR153","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1073\/pnas.1411393111","volume":"111","author":"JE Zuckerman","year":"2014","unstructured":"Zuckerman JE, et al. Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A. 2014;111(31):11449\u201354.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00660-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00660-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00660-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:04:16Z","timestamp":1789985056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00660-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":153,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00660-8","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ChatGPT (OpenAI) and Grammarly were used solely for language editing, grammar correction, and improving textual clarity. The authors critically reviewed and verified all scientific content, references and interpretations and take full responsibility for the final manuscript. No professional medical writing agency or external medical writer was involved in the preparation of this article.","order":1,"name":"Ethics","label":"AI use declarations","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}],"article-number":"81"}}